from the most accredited expert in igf 1 Zvi Laronz to me.
(e mail)
Dear Mr. Salcedo,
In reply to your question, there are no studies in man (LR3) to the best of my knowledge. Some of the IGF-I analogues have been found to be potent mitogens. What is the reason you asked? Do you have any patients?
We are at present performing a worldwide survey on the prevalence of malignancy in patients with IGF-I deficiency and their family relatives. If you see or know such patients I would appreciate your cooperation in providing us data on a simple questionnaire.
Please reply and we shall send you further details.
Best regards,
Zvi Laron, MD
_______________________
Prof. Zvi Laron
Endocrinology and Diabetes Research Unit,
Schneider Children's Medical Center
Petah-Tikva 49202
Israel
----------------------------------
example of his works:
Insulin-like growth factor 1 (IGF-1): a growth hormone
Z Laron
Endocrinology and Diabetes Research Unit, WHO Collaborating Center for the Study of Diabetes in Youth, Schneider Children's Medical Center, Tel Aviv University, 14 Kaplan Street, Petah Tikva 49202, Tel Aviv, Israel
Professor Laron:
AimTo contribute to the debate about whether growth hormone (GH) and insulin-like growth factor 1 (IGF-1) act independently on the growth process.
MethodsTo describe growth in human and animal models of isolated IGF-1 deficiency (IGHD), such as in Laron syndrome (LS; primary IGF-1 deficiency and GH resistance) and IGF-1 gene or GH receptor gene knockout (KO) mice.
ResultsSince the description of LS in 1966, 51 patients were followed, many since infancy. Newborns with LS are shorter (4247 cm) than healthy babies (4952 cm), suggesting that IGF-1 has some influence on intrauterine growth. Newborn mice with IGF-1 gene KO are 30% smaller. The postnatal growth rate of patients with LS is very slow, the distance from the lowest normal centile increasing progressively. If untreated, the final height is 100136 cm for female and 109138 cm for male patients. They have acromicia, organomicria including the brain, heart, gonads, genitalia, and retardation of skeletal maturation. The availability of biosynthetic IGF-1 since 1988 has enabled it to be administered to children with LS. It accelerated linear growth rates to 89 cm in the first year of treatment, compared with 1012 cm/year during GH treatment of IGHD. The growth rate in following years was 56.5 cm/year.
ConclusionIGF-1 is an important growth hormone, mediating the protein anabolic and linear growth promoting effect of pituitary GH. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.
Key Words: insulin-like growth factor I growth hormones Laron syndrome growth
---------------------------------------------
..........OBJECTIVE KNOWLEGDE.
